AAAAAA

   
Results: 1-17 |
Results: 17
Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2 '-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke
Authors: Smith, CJ Fischer, TH Heavner, DL Rumple, MA Bowman, DL Brown, BG Morton, MJ Doolittle, DJ
Citation: Cj. Smith et al., Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2 '-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke, TOXICOL SCI, 59(2), 2001, pp. 316-323
Hepatic lipase as a focal point for the development and treatment of coronary artery disease
Authors: Zambon, A Brown, BG Deeb, SS Brunzell, JD
Citation: A. Zambon et al., Hepatic lipase as a focal point for the development and treatment of coronary artery disease, J INVES MED, 49(1), 2001, pp. 112-118
Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL
Authors: Cheung, MC Zhao, XQ Chait, A Albers, JJ Brown, BG
Citation: Mc. Cheung et al., Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL, ART THROM V, 21(8), 2001, pp. 1320-1326
Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI - A case-control study
Authors: Zhao, XQ Yuan, C Hatsukami, TS Frechette, EH Kang, XJ Maravilla, KR Brown, BG
Citation: Xq. Zhao et al., Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI - A case-control study, ART THROM V, 21(10), 2001, pp. 1623-1629
Plasma phospholipid transfer protein activity in patients with low HDL andcardiovascular disease treated with simvastatin and niacin
Authors: Cheung, MC Wolfbauer, G Kennedy, H Brown, BG Albers, JJ
Citation: Mc. Cheung et al., Plasma phospholipid transfer protein activity in patients with low HDL andcardiovascular disease treated with simvastatin and niacin, BBA-MOL BAS, 1537(2), 2001, pp. 117-124
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
Authors: Brown, BG Zhao, XQ Chait, A Fisher, LD Cheung, MC Morse, JS Dowdy, AA Marino, EK Bolson, EL Alaupovic, P Frohlich, J Albers, JJ Serafini, L Huss-Frechette, E Wang, S DeAngelis, D Dodek, A
Citation: Bg. Brown et al., Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N ENG J MED, 345(22), 2001, pp. 1583-1592
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment
Authors: Zambon, A Deeb, SS Brown, BG Hokanson, JE Brunzell, JD
Citation: A. Zambon et al., Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment, CIRCULATION, 103(6), 2001, pp. 792-798
The effect of a 2-h exposure to cigarette smoke on the metabolic activation of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mice
Authors: Brown, BG Richter, E Tricker, AR Ayres, PH Doolittle, DJ
Citation: Bg. Brown et al., The effect of a 2-h exposure to cigarette smoke on the metabolic activation of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mice, CHEM-BIO IN, 138(2), 2001, pp. 125-135
Electron-beam tomography coronary calcium scores are superior to Framingham risk variables for predicting the measured proximal stenosis burden
Authors: Brown, BG Morse, J Zhao, XQ Cheung, M Marino, E Albers, JJ
Citation: Bg. Brown et al., Electron-beam tomography coronary calcium scores are superior to Framingham risk variables for predicting the measured proximal stenosis burden, AM J CARD, 88(2A), 2001, pp. 23E-26E
Who qualifies as a software engineer?
Authors: Brown, BG
Citation: Bg. Brown, Who qualifies as a software engineer?, COMPUTER, 33(1), 2000, pp. 9-9
Lipid therapy to stabilize the vulnerable atherosclerotic plaque - New insights into the prevention of cardiovascular events
Authors: Brown, BG Zhao, XQ
Citation: Bg. Brown et Xq. Zhao, Lipid therapy to stabilize the vulnerable atherosclerotic plaque - New insights into the prevention of cardiovascular events, CHOLESTEROL-LOWERING THERAPY, 2000, pp. 249-272
The effect of cotinine or cigarette smoke co-administration on the formation of O-6-methylguanine adducts in the lung and liver of A/J mice treated with 4-methylnitrosamino)-1-(3-pyridyl)-1-1butanone (NNK) (vol 47, pg 33, 1999)
Authors: Brown, BG Chang, CJG Ayres, PH Lee, CK Doolittle, DJ
Citation: Bg. Brown et al., The effect of cotinine or cigarette smoke co-administration on the formation of O-6-methylguanine adducts in the lung and liver of A/J mice treated with 4-methylnitrosamino)-1-(3-pyridyl)-1-1butanone (NNK) (vol 47, pg 33, 1999), TOXICOL SCI, 50(1), 1999, pp. 153-153
The effect of cotinine or cigarette smoke co-administration on the formation of O-6-methylguanine adducts in the lung and liver of A/J mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
Authors: Brown, BG Chang, CJG Ayres, PH Lee, CK Doolittle, DJ
Citation: Bg. Brown et al., The effect of cotinine or cigarette smoke co-administration on the formation of O-6-methylguanine adducts in the lung and liver of A/J mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), TOXICOL SCI, 47(1), 1999, pp. 33-39
Relationship between plasma phospholipid transfer protein activity and HDLsubclasses among patients with low HDL and cardiovascular disease
Authors: Cheung, MC Wolfbauer, G Brown, BG Albers, JJ
Citation: Mc. Cheung et al., Relationship between plasma phospholipid transfer protein activity and HDLsubclasses among patients with low HDL and cardiovascular disease, ATHEROSCLER, 142(1), 1999, pp. 201-205
Evidence for a new pathophysiological mechanism for coronary artery disease regression - Hepatic lipase-mediated changes in LDL density
Authors: Zambon, A Hokanson, JE Brown, BG Brunzell, JD
Citation: A. Zambon et al., Evidence for a new pathophysiological mechanism for coronary artery disease regression - Hepatic lipase-mediated changes in LDL density, CIRCULATION, 99(15), 1999, pp. 1959-1964
Angiographic trials of lipid-lowering therapy
Authors: Brown, BG Zhao, XQ Albers, JJ
Citation: Bg. Brown et al., Angiographic trials of lipid-lowering therapy, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 659-672
Importance of endothelial function in mediating the benefits at lipid-lowering therapy
Authors: Brown, BG Zhao, XQ
Citation: Bg. Brown et Xq. Zhao, Importance of endothelial function in mediating the benefits at lipid-lowering therapy, AM J CARD, 82, 1998, pp. 49T-52T
Risultati: 1-17 |